A biopsy is the most common method used to diagnose different types of cancer. A biopsy is done by removing a small amount of issue and several steps are taken before a pathologist makes a diagnosis. However, the arrival of advanced imaging techniques has taken the cancer tissue diagnostics to a different level. The arrival of revolutionary diagnostics platforms is gaining popularity in the cancer tissue diagnostics.
According to the report by Future Market Insights (FMI), the global cancer tissue diagnostics market is expected to register nearly $9,650 million by the end of 2026, growing at 8.3% CAGR during 2016-2026.
FDA gives nod to first NGS-based test to screen for non-small cell lung cancer therapies
The Food and Drug Administration (FDA) based in the U.S. has approved Thermo Fisher Scientific’s Oncomine Dx Tagret Test, the first NSG-based test which monitors tumor samples for biological marker related with three approved therapies by FDA for Non-Small Cell Lung Cancer (NSCLC). The test assesses 23 genes related to NSCLC. The test will help oncologists to determine the patients who can be treated. It will also help them to select the type of treatment within a few days instead of weeks.
The test has been developed in partnership with Pfizer and Novartis. The test is based on Thermo Fisher’s Ion AmpliSeq technology that helps in screening tumor samples for multiple genetic markers with 10 nanograms of nucleic acid. Moreover, Ion PGM Dx System by Thermo Fisher Scientific will be used to run all tests.
New tests to detect cancer at early stage
Bioengineers at the University of California have discovered a new blood test that can detect tumor DNA in blood and its location. The test uses the DNA released by cancer cells into the bloodstream. This helps to identify the affected tissue.
Researchers at Johns Hopkins are working on a tool that can be used to identify molecular traces of cancer even in the people who show no signs or symptoms of cancer.
Scientists in Israel have developed a cost-effective technology to detect gastric cancer at an early stage. With help of technology, five chemicals are analysed that indicate cancer in exhaled breath.
MIT engineers have come up with the urine test using nanoparticle-coated paper, similar to a pregnancy test. This test can reveal within few minutes if person undergone a test has cancer.
With increasing number of biomarkers that are used to detect cancer at an early stage, new cancer biomarkers test are expected in cancer tissue diagnostics in the coming years. For example, researchers at the University of Sheffield have identified around 700 new blood biomarkers that can be used to detect cancer at an early stage.
However, need for huge investments in the development of high-end instruments such as MRI, SPECT, etc., and analytical instruments used in laboratories are the biggest factors hampering the growth of cancer tissue diagnostics market. Moreover, leading diagnostics companies are facing a competition from big pharma companies entering into diagnostics business.